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Abstract
Background:  We describe type-specific progression, regression and persistence of incident
human papillomavirus (HPV)-6-11-16 and -18 infections, along with type distribution in cervical
intra-epithelial neoplasia (CIN) lesions.
Methods: The study population consisted of 16–23 year-old women undergoing Pap testing and
cervical swab polymerase chain reaction testing for HPV DNA at approximate 6 month intervals
for up to 4 years in the placebo arm of a clinical trial of an HPV 16-vaccine. HPV types in incident
infections were correlated with types in lesion biopsy specimens.
Results: 56.7% of CIN-1 and nearly one-third of CIN-2/3 lesions following incident HPV-6-11-16
or -18 infections did not correlate with the incident infection HPV type. Cumulative 36-month
progression rates to CIN-2/3 testing positive for the relevant HPV type were highest for HPV-16
infections (16.5%), followed by HPV-18 (8.2%). Overall, 26.0% of CIN-1, 50.0% of CIN-2 and 70.6%
of CIN-3 biopsies tested positive for HPV-6-11-16-18 infections.
Conclusion: Women with a given HPV type may often be co-infected or subsequently infected
with other types which may lead to subsequent cervical lesions. This issue has been addressed in
this study reporting data for the natural history of HPV-6-11-16 and -18 infections and is a relevant
consideration in designing future studies to evaluate the incidence/risk of CIN following other type-
specific HPV infections.
Background
Cervical cancer is the second most common cancer in
women worldwide[1] and is caused by human papilloma-
virus (HPV) infection[2]. Organized screening using the
Pap test has reduced cervical cancer rates in industrialized
countries[3]. Because Pap testing does not address the
root cause of cervical cancer (i.e., HPV infection), screen-
ing shifts the clinical burden of HPV disease from treating
cancers to managing a large number of precancerous
lesions[4,5]. It has been estimated that approximately
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400,000 new cases of cervical intraepithelial neoplasia
(CIN) are diagnosed in the United States each year, with
annual costs of approximately $2.3 billion for cervical
cancer screening and $700 million for CIN treatment[6].
The diagnosis and treatment of CIN can lead to anxiety
concerning cancer risk and sexual functioning[7,8].
Prophylactic vaccines targeting HPV 6/11/16/18[9] and
HPV 16/18 infections[10] have recently been shown to
reduce the incidence of CIN due to these types. Policy-
makers worldwide are also evaluating technologies
designed to enhance the diagnosis of CIN such as HPV
tests and liquid-based cytology[11]. Data on the natural
history of HPV infection are therefore critical for the eval-
uation of these and other emerging technologies.
The present study describes the type-specific progression
and regression of incident HPV 6, 11, 16 and 18 infec-
tions, along with the observed distribution of these HPV
types in CIN grade 1–3 lesions. A unique feature of the
present study with respect to prior analyses of HPV infec-
tion natural history [12-15] is the correlation of HPV type
observed in the incident infection with that detected in
cervical lesion tissue specimens. Although the detection of
CIN-1 lesions following HPV infection have received less
attention than CIN-2/3 due to their lower oncogenic
potential, a recent US study reported that more than half
of women with incident CIN-1 were treated in clinical
practice[16]. Policy models of HPV disease and costs have
thus typically considered sub-clinical HPV infections
(without clinically detectable CIN-1) as a distinct health
state from progression to clinically detectable CIN-1 and
we follow this dichotomy in the present study[17,18]. In
this regard, a study of women with active HPV 6, 11, 16
and 18 infections undergoing colposcopy found that CIN-
1-3 lesions were detected in 10%, suggesting that most
HPV infections are not synonymous with clinically detect-
able CIN[19].
Methods
Study participants and procedures
The current evaluation focuses on women enrolled in the
placebo arm of a randomized double-blind clinical trial of
an HPV-16 vaccine (Merck Research Laboratories). The
study population and trial design have been described
elsewhere [19-22]. Briefly, the population consisted of
2,391 US women who on day 1 of the trial were 16–23
years of age, and did not report a history of pregnancy,
abnormal Pap tests or more than 5 lifetime male sex part-
ners. At enrollment, women provided written informed
consent. The study was conducted in conformance with
applicable federal and local requirements regarding ethi-
cal committee review and protection of human subjects
participating in biomedical research. Women in the pla-
cebo arm received intramuscular injections visually indis-
tinguishable from vaccine.
Women underwent type-specific endo/ecto-cervical swab
HPV polymerase chain reaction (PCR) testing for HPV 6,
11, 16 and 18 infections at approximate 6 month intervals
through 48 months of follow-up. The HPV testing meth-
ods utilized have been described in detail elsewhere
[21,22]. Briefly, cervical swabs were prepared for PCR
using a QIAamp DNA Blood kit (QIAGEN, Inc., Valencia,
CA). DNA was analyzed by qualitative PCR using HPV 6,
11, 16 and 18 type-specific and gene-specific primers
based on the L1, E6 and E7 genes for these types[20]. Beta-
globin PCR assay was performed to verify that purified
samples contained a sufficient quality and quantity of
DNA for PCR amplification. PCR products were dot-blot-
ted, hybridized to the corresponding 32P-labeled β-globin
or HPV 6/11/16/18 gene-specific oligonucleotide, and
visualized by autoradiography. Appropriate negative and
positive controls were run with each assay and any speci-
men testing positive for at least 2 of the 3 genes was con-
sidered positive. Specimens testing positive for only 1
gene were considered positive if, on retesting, they were
positive for 2 or 3 genes or the same single gene. Labora-
tory validation studies rigorously evaluated assay sensitiv-
ity against known copy number type- and gene-specific
plasmids. The assay was shown to have a greater than 95%
probability of detecting at least 13 copies per sample, with
95% upper confidence bounds for sample false negativity
and false positivity of 0.7% and 0.8% respectively. All
PCR assays were performed at Merck Research Laborato-
ries (West Point, PA).
At visits where swab samples were obtained, cervical sam-
ples were also collected for liquid-based cytology (Thin-
Prep™, Cytyc) testing. An algorithm was used to guide
further evaluation for cytologic findings. A single Pap test
result of high-grade squamous intraepithelial lesion
(HSIL), or repeated Pap tests showing low-grade lesions
(LSIL) or atypical squamous cells of undetermined signif-
icance (ASCUS), prompted colposcopy. Investigators were
allowed to manage single ASC-US and LSIL results based
on local standards of care. All women attending the
month 48 trial visit were referred for colposcopy, with
biopsy performed if a CIN lesion was suspected. Cervical
biopsy specimens were processed and assigned histologic
diagnoses for purposes of medical management by central
laboratory pathologists, and were typed by PCR for HPV
6, 11, 16 and 18 [20-22]. A multiplex PCR assay was used
for HPV typing of biopsy specimens. This assay has previ-
ously been shown to be more sensitive than the Roche
(Alameda, CA) reverse line blot PCR assay[23] with a limit
of detection for HPV DNA of 6.1, 7.7, 5.5 and 6.5 copies
per test for HPV 6, 11, 16 and 18 respectively[24]. The
detection limit was defined as the lowest HPV copyInfectious Agents and Cancer 2007, 2:15 http://www.infectagentscancer.com/content/2/1/15
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number for which the one-sided lower 95% confidence
bound on the probability of a positive PCR result
exceeded 95%.
Measures
Incident HPV 6, 11, 16 and 18 infections were identified
on cervical swab or biopsy specimens among woman neg-
ative for the relevant HPV type on their first 2 study swabs
and any cervical biopsy specimens obtained on or prior to
the second swab. Routine cervical swab HPV testing
occurred at discrete intervals within the trial (approxi-
mately every 6 months). It is likely that initial positive
HPV test results observed on a particular date reflected
HPV infections that originated at some indeterminate
time point between the last negative and initial positive
test results. Consistent with our and others' earlier
work,[19,25,26] we therefore assumed HPV infections
occurred at the mid-point between the initial positive test
date and the previous negative test, (please see figure 1).
Incident HPV infections were examined until either the
detection of a CIN-1-3 lesion for which the cervical biopsy
specimen tested PCR positive for the relevant HPV type
("progression"), or a negative cervical swab HPV test
result(s) for that type ("regression"). Because women were
required to have two consecutive negative swabs for a
given HPV type prior to the start of an incident infection,
if two consecutive negative swabs for that type were sub-
sequently observed, the infection was assumed to have
cleared at the midpoint in time between the final positive
test and first negative swab result. However, there were
also women with positive swab sample(s) for a given type
followed by only a single negative swab prior to the trial
concluding or their withdrawal. Among women with inci-
dent HPV-6 infections, 19 (18.4%) fell into this category,
compared to 2 (15.4%), 16 (11.3%) and 9 (14.5%) with
HPV-11, 16 and 18.
Since these women lacked two consecutive negative
swabs, some previous analyses have evaluated them as
censored at the date of the negative swab[27]. However,
this would be expected to considerably under-estimate the
actual regression rate of infection for these women. In
actuality many would likely have cleared their infection
around the time of their last positive swab and differ with
respect to their subsequent course from women who were
otherwise censored with a positive swab at their last trial
visit. For instance, among 63 women with an incident
HPV-6 infection followed by a negative swab sample, and
at least one additional study swab, only 2 (3.2%) had a
non-negative HPV-6 result on the second swab or a con-
current biopsy specimen. Similarly, for HPV-11, -16 and -
18 infections the proportions were 0/6 (0.0%), 8/76
(10.5%) and 3/31 (9.7%). This would suggest that nearly
all women with only a single negative HPV test at the con-
clusion of trial follow-up would have previously cleared
their infections. We therefore evaluated these women as
having cleared their infections at the midpoint in time
between their final positive test and first negative swab
result. Women observed to have positive swab or biopsy
specimens, followed by a single negative swab, followed
by a positive swab or biopsy specimen, were analyzed as
having persistent infections. Women with a positive test
on the date of their final trial swab sample were evaluated
as censored.
From among all placebo-arm women diagnosed with CIN
during the course of the trial, the prevalence of HPV 6, 11,
16 and/or 18 infections in CIN-1-3 lesions was estimated
using PCR from the first biopsy diagnosis of CIN observed
in the trial for each woman. Only the first CIN biopsy
specimen was chosen for each woman to avoid selecting
data for the same lesion multiple times in cases in which
more than one biopsy specimen was taken during the
course of follow-up. If multiple grades of CIN were
observed for a woman among biopsies on a given date,
the most severe histologic diagnosis was selected. HPV
status for types other than 6, 11, 16 and 18 was unavaila-
ble.
Results were compared to data from previous US studies
of the prevalence of type-specific HPV infections in
biopsy-confirmed CIN lesions. Studies included per-
formed PCR typing for multiple HPV types on cervical
lesion tissue specimens. Analyses based on endo/ecto-cer-
vical swab or lavage were excluded based on the increased
potential for detecting HPV types unrelated to the cervical
lesion of interest. To avoid double-counting in estimating
the fraction of lesions attributable to individual or groups
of HPV types, in instances where multiple HPV types were
observed in a single lesion, the following procedure was
undertaken. Each lesion testing positive for multiple HPV
types was fractionally attributed to individual HPV types
based on the relative proportion of lesions observed in
each study to test positive for each single-type infection
only, for that grade of lesion. For instance, if within a
given study, a CIN-2/3 lesion tested positive for HPV types
6 and 16 and the number of single type-infected CIN-2/3
lesions for HPV-6 and -16 were 1 and 19 respectively, then
(1/20) and (19/20) of the lesion was attributed to HPV-6
and -16.
Statistical analysis
The cumulative proportion of HPV infections persisting
without evidence of CIN, progressing to CIN 1, 2 and 3
and regressing, at 12, 24 and 36 months post-infection
were estimated using Kaplan-Meier (K-M) methods[28].
Each outcome of persistent HPV infection was mutually
exclusive. Thus, once an endpoint of progression to CIN
1, 2 or 3 was observed, a woman was no longer at risk forInfectious Agents and Cancer 2007, 2:15 http://www.infectagentscancer.com/content/2/1/15
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contributing towards the cumulative rate of regression,
and vice versa. Ninety-five percent confidence intervals for
cumulative proportions persisting, progressing and
regressing were estimated through non-parametric boot-
strapping of the K-M survivorship function with 1,000
replicates[29].
Results
Among 1,203 women in the placebo arm of the trial who
underwent cervical swab HPV PCR testing at enrollment,
the prevalence of individual HPV types was as follows:
HPV-6 (3.2%), HPV-11 (0.5%), HPV-16 (6.8%), HPV-18
(2.6%). The combined baseline prevalence of HPV 6, 11,
16 and 18 infections was 12.1%.
Characteristics of women with incident HPV-6 (n = 103),
11 (n = 13), 16 (n = 142) and 18 (n = 62) infections are
presented in Table 1. Samples eligible for each type-spe-
cific analysis were generally similar. The median number
of lifetime sexual partners at the time of incident HPV
infection was five.
Following the date of their incident HPV 6, 11, 16, and 18
infections, women averaged an additional 21.2, 16.1,
22.1 and 21.4 months of follow-up respectively. The
number of CIN lesions testing positive or negative for the
HPV type observed in the incident infection, during the
subsequent course of follow-up, is reported in Table 2.
Overall, more than half of CIN-1 lesions were negative for
the HPV type observed in the incident infection, com-
pared to nearly one-third of CIN-2/3 lesions. Only for
analyses of CIN-2/3 lesions following incident HPV-16
infections was there a high type-specific concordance
(85.0%). The average estimated time from onset of each
type-specific infection to a CIN-1 (9.3 months) or CIN-2/
3 (11.8 months) lesion positive for the same type was
observed to be shorter than for instances where a CIN-1
(16.5 months) or CIN-2/3 lesion (17.2 months) was
detected that was negative for the relevant type. However,
there was also substantial overlap in times to CIN detec-
tion, with the interquartile range (25th–75th percentile) of
times to detection of type-concordant CIN-2/3 lesions
covering the 10th to 70th percentiles of times to detection
of type-discordant CIN-2/3.
The cumulative proportion of females with incident HPV
6, 11, 16 and 18 infections progressing to CIN-1-3 testing
positive for the relevant HPV type on biopsy, persisting
with type-specific infection in the absence of detected
CIN, or regressing to negative for HPV infection for the
relevant type on a cervical swab, at 12, 24 and 36 months
of follow-up is presented in Table 3. Cumulative 36-
month progression rates to CIN-1 ranged from 0.0% for
HPV-11 to 20.7% for HPV-16. Progression rates over 36
months to CIN-2/3 were highest for HPV-16 infections
(16.5%), followed by HPV-18 (8.2%). No women were
Table 1: Demographic and behavioral characteristics of eligible women with incident HPV 6, 11, 16 or 18 infections
Variable HPV 6 N = 103 n (%) HPV 11 N = 13 n (%) HPV 16 N = 142 n (%) HPV 18 N = 62 n (%)
Age Group
16–19 6 (5.8) 0 (0.0) 13 (9.2) 8 (12.9)
20–23 77 (74.8) 7 (53.9) 95 (66.9) 43 (69.4)
24–27 20 (19.4) 6 (46.1) 34 (23.9) 11 (17.7)
Race
Black 6 (5.8) 1 (7.7) 10 (7.0) 3 (4.8)
Hispanic 8 (7.8) 3 (23.1) 12 (8.5) 7 (11.3)
Other 4 (3.9) 1 (7.7) 8 (5.6) 2 (3.2)
White 85 (82.5) 8 (61.5) 112 (78.9) 50 (80.7)
Smoking Status
Current Smoker 37 (35.9) 3 (23.1) 45 (31.7) 27 (43.6)
Ex-Smoker 18 (17.5) 4 (30.8) 28 (19.7) 9 (14.5)
Non-Smoker 48 (46.6) 6 (46.2) 69 (48.6) 26 (41.9)
Age at first sexual intercourse
≤ 14 4 (3.9) 1 (7.7) 13 (9.2) 9 (14.5)
15–18 76 (73.9) 10 (76.9) 105 (73.9) 46 (74.2)
≥ 19 23 (22.3) 2 (15.4) 24 (16.9) 7 (11.3)
Lifetime Number of Sexual 
Partners
1 7 (6.8) 1 (7.7) 12 (8.5) 2 (3.2)
2–3 23 (22.3) 5 (38.5) 24 (16.9) 11 (17.8)
4–6 47 (45.7) 7 (53.8) 73 (51.4) 35 (56.4)
7–9 21 (20.4) 0 (0.0) 27 (19.0) 10 (16.1)
10–14 5 (4.8) 0 (0.0) 6 (4.2) 4 (6.4)
HPV = human papillomavirusInfectious Agents and Cancer 2007, 2:15 http://www.infectagentscancer.com/content/2/1/15
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diagnosed with invasive cervical cancer. By 36 months all
HPV 6, 11 and 16 infections had either regressed, or pro-
gressed to CIN, with 8.2% of HPV-18 infections persist-
ing. The cumulative regression rate was highest for HPV-
11 (100.0%) and lowest for HPV-16 (62.8%).
Among all placebo arm women diagnosed with CIN (n =
267), regardless of HPV status, there were 442 CIN-1-3
cervical biopsy specimens. From the first CIN biopsy spec-
imens obtained for these 267 women, 22 (8.2%) lacked
HPV typing. This left an eligible sample of 245 initial CIN
biopsies, of which 192 were CIN-1, 36 CIN-2 and 17 CIN-
3. Overall, 26.0% of CIN-1, 50.0% of CIN-2 and 70.6% of
CIN-3 biopsies tested PCR-positive for HPV 6, 11, 16 or
18 (Table 4). Of lesions testing positive for these types, 5
(4.9%) were observed to test positive for more than one
of these types. No CIN cases tested positive for HPV-11.
HPV-6, in the absence of HPV-16 and/or 18 co-infection,
was observed in 5.2% of CIN-1, 5.6% of CIN-2 and 5.9%
of CIN-3 cases.
The overall estimated proportion of CIN-1 lesions attrib-
utable to HPV 6, 11, 16 and 18 infections (25.0%) in prior
US studies (Table 5) was nearly identical to that observed
in the present analysis (26.0%). For CIN-2/3, the esti-
mated proportion of lesions attributable to these four
types was also relatively similar between the present
(56.6%) and prior (63.6%) studies. However, no prior
studies documented the presence of HPV-6 in CIN-2/3
lesions. Only two of the seven prior studies, by Evans et al.
(1 CIN-1) and Hu et al. (5 CIN-1, 14 CIN-2/3), reported
lesions explicitly identified as containing multiple HPV
types[30,31]. One additional US study of CIN-2/3 lesions
was excluded from the analysis as 67% of lesions were
reported as testing positive for multiple HPV types (41%
double/26% triple infections), suggestive of potential
Table 3: Type-specific persistence, regression and progression of incident HPV 6, 11, 16, 18 infections
Proportion 
Persisting Without 
CIN Due to Type 
(95% CI)
Proportion for 
Which Type 
Regressed (95% CI)
Proportion 
Progressed to CIN 
1 Due to Type 
(95% CI)
Proportion 
Progressed to CIN 
2 Due to Type 
(95% CI)
Proportion 
Progressed to CIN 
3 Due To Type 
(95% CI)
HPV 6 (n = 103)
12 Months 26.0 (17.5, 35.0) 62.3 (52.9, 71.8) 9.6 (4.0, 15.5) 2.1 (0.0, 5.5) 0.0 (-)
24 Months 0.0 (-) 84.0 (75.5, 91.3) 13.9 (6.7, 21.1) 2.1 (0.0, 5.5) 0.0 (-)
36 Months 0.0 (-) 84.0 (75.5, 91.3) 13.9 (6.7, 21.1) 2.1 (0.0, 5.5) 0.0 (-)
HPV 11 (n = 13)
12 Months 14.6 (0.0, 42.9) 85.4 (57.1, 100.0) 0.0 (-) 0.0 (-) 0.0 (-)
24 Months 0.0 (-) 100.0 (-) 0.0 (-) 0.0 (-) 0.0 (-)
36 Months 0.0 (-) 100.0 (-) 0.0 (-) 0.0 (-) 0.0 (-)
HPV 16 (n = 142)
12 Months 47.2 (37.9, 56.6) 35.4 (27.3, 44.5) 10.5 (5.7, 16.5) 4.5 (1.0, 8.6) 2.4 (0.0, 5.5)
24 Months 15.8 (8.6, 24.8) 53.0 (43.5, 63.2) 18.3 (11.5, 26.0) 9.1 (3.8, 14.8) 3.8 (0.8, 8.2)
36 Months 0.0 (0.0, 7.1) 62.8 (50.0, 73.1) 20.7 (12.1, 29.6) 9.1 (3.8, 14.8) 7.4 (1.9, 14.0)
HPV 18 (n = 62)
12 Months 52.9 (38.9, 67.1) 34.8 (22.3, 48.2) 6.8 (1.6, 13.7) 5.5 (0.0, 12.2) 0.0 (-)
24 Months 16.3 (5.3, 28.7) 66.0 (51.4, 79.0) 9.5 (1.9, 18.5) 5.5 (0.0, 12.2) 2.7 (0.0, 9.6)
36 Months 8.2 (0.0, 23.1) 74.1 (55.9, 89.5) 9.5 (1.9, 18.5) 5.5 (0.0, 12.2) 2.7 (0.0, 9.6)
CIN = cervical intraepithelial neoplasia; HPV = human papillomavirus; CI = confidence interval
Table 2: Number of incident HPV 6, 11, 16 and 18 infections with subsequent CIN lesions testing positive or negative for the HPV type 
observed in the incident infection
HPV Type CIN 1-Positive for type 
(% of CIN1)
CIN 1-Negative for type* 
(% of CIN 1)
CIN 2/3-Positive for type 
(% of CIN 2/3)
CIN 2/3-Negative for type* 
(% of CIN 2/3)
HPV 6 14 (43.8%) 18 (56.2%) 2 (28.6%) 5 (71.4%)
HPV 11 0 (0.0%) 3 (100.0%) 0 (-) 0 (-)
HPV 16 23 (51.1%) 22 (48.9%) 17 (85.0%) 3 (15.0%)
HPV 18 5 (29.4%) 12 (70.6%) 4 (57.1%) 3 (42.9%)
Total 42 (43.3%) 55 (56.7%) 23 (67.6%) 11 (32.4%)
* Percentages negative for type refer to the proportion of CIN 1 and CIN 2/3 cases that tested negative for the HPV type listed in that row at left.
CIN = cervical intraepithelial neoplasia; HPV = human papillomavirusInfectious Agents and Cancer 2007, 2:15 http://www.infectagentscancer.com/content/2/1/15
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problems with testing methods for the 3 HPV types exam-
ined[32].
Discussion
This analysis has described type-specific progression, per-
sistence and regression of incident HPV 6, 11, 16 and 18
infections, along with the observed distribution of these
HPV types in CIN-1-3 lesions. To our knowledge, this is
the first analysis to examine the type-specific detection of
histologically confirmed CIN-1 following incident HPV
infections, and to correlate the HPV type observed in inci-
dent HPV infections with that subsequently detected in
cervical lesion tissue specimens in estimating progression
rates. The perspective adopted is particularly useful for
informing HPV disease natural history models used in
policy evaluations of emerging technologies[17,18,33].
A salient inference from this analysis is that women
infected with a given HPV type are often co-infected or
subsequently infected with other HPV types which may be
responsible for subsequent cervical lesions. This was espe-
cially true for CIN-1, where the majority of detected
lesions following incident HPV 6, 11, 16 or 18 infections
did not correlate with the incident infection HPV type,
however was also observed for nearly one-third of CIN-2/
3 cases.
Table 5: Percent of CIN cases estimated to be attributable to nine specific HPV types & any HPV type in prior US studies
% of Cases Estimated to be Attributable to Specific HPV types
Year Author N Testing Method HPV 6 HPV 11 HPV 16 HPV 18 HPV 31 HPV 33 HPV 45 HPV 52 HPV 58 Any HPV type*
CIN 1 30,31,39–41,43
2006 Srodon, M 36 PCR/Biopsy 2.8 2.8 11.1 16.7 5.6 5.6 5.6 2.8 2.8 100.0
2005 Hu, L† 45 PCR/Biopsy 6.4 2.2 3.1 0.0 2.2 12.2 7.2 87.0
2002 Evans, M† 28 PCR/Biopsy 4.5 3.6 7.1 3.6 7.1 3.6 3.6 7.1 0.0 100.0
1998 Aoyama, C 11 PCR/Biopsy 0.0 0.0 27.3 9.1 9.1 9.1 54.5
1998 Quade, B 30 PCR/Biopsy 3.3 3.3 10.0 3.3 6.7 0.0 0.0 0.0 0.0 73.3
1996 Isacson, C 40 PCR/Biopsy 5.0 10.0
Total 190 3.6 4.8 9.9 6.7 5.6 2.7 2.9 6.1 3.0 87.4
CIN 2/3 30,31,39–43
2006 Srodon, M 116 PCR/Biopsy 0.0 0.0 75.0 4.3 5.2 1.7 0.0 0.9 3.4 100.0
2005 Hu, L† 97 PCR/Biopsy 38.9 9.6 11.6 1.0 1.1 5.0 2.6 93.6
2002 Evans, M 22 PCR/Biopsy 0.0 0.0 68.2 4.5 9.1 4.5 4.5 0.0 4.5 100.0
1998 Aoyama, C 21 PCR/Biopsy 0.0 0.0 52.4 0.0 19.0 19.0 95.2
1998 Quade, B 19 PCR/Biopsy 0.0 0.0 52.6 5.3 0.0 15.8 0.0 0.0 0.0 78.9
1996 Isacson, C 11 PCR/Biopsy 0.0 0.0 45.5 0.0 18.2 9.1 0.0 0.0 0.0 100.0
1993 Shroyer, K 13 PCR/Biopsy 0.0 0.0 61.5 0.0 92.3
Total 299 0.0 0.0 58.1 5.5 8.8 4.2 0.8 2.2 2.8 95.9
* As determined by consensus PCR primers sensitive to positivity for at least 10 HPV types.
† Lesions in these studies containing multiple HPV types were fractionally attributed to individual HPV types as described in the Methods section. 
Without this method of attribution, original figures for HPV prevalence differing from those reported in the table were as follows: Evans et al., CIN 
1 (HPV 6 – 7.1%); Hu et al., CIN 1 (HPV 16 – 8.9%, 31 – 6.7%, 52 – 13.3%, 58 – 11.1%), CIN 2/3 (HPV 16 – 40.2%, 18 – 12.4%, 31 – 13.4%, 45 – 
2.1%, 52 – 8.2%, 58 – 6.2%)
CIN = cervical intraepithelial neoplasia; HPV = human papillomavirus; PCR = polymerase chain reaction
Table 4: Prevalence of HPV 6, 11, 16 and 18 infections in CIN 1–
3 lesions
Histologic Diagnosis/HPV Type(s) n (%)
CIN 1
HPV 6 10 (5.2)
HPV 6 and 16 1 (0.5)
HPV 6, 16 and 18 1 (0.5)
HPV 16 30 (15.6)
HPV 16 and 18 1 (0.5)
HPV 18 7 (3.6)
Negative for HPV 6, 11, 16 and 18 142 (74.0)
Total 192 (100.0)
CIN 2
HPV 6 2 (5.6)
HPV 6 and 16 1 (2.8)
HPV 16 12 (33.3)
HPV 18 3 (8.3)
Negative for HPV 6, 11, 16 and 18 18 (50.0)
Total 36 (100.0)
CIN 3
HPV 6 1 (5.9)
HPV 16 10 (58.8)
HPV 16 and 18 1 (5.9)
Negative for HPV 6, 11, 16 and 18 5 (29.4)
Total 17 (100.0)
HPV = human papillomavirus; CIN = cervical intraepithelial neoplasiaInfectious Agents and Cancer 2007, 2:15 http://www.infectagentscancer.com/content/2/1/15
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Prior studies of the natural history of incident HPV infec-
tions have generally not performed HPV typing of CIN
lesion tissue specimens and have thus estimated results
based on all lesions observed, regardless of HPV type, fol-
lowing detection of a given infection[12,15]. This perspec-
tive can be clinically useful for assessing the overall risk of
being subsequently diagnosed with cervical neoplasia for
women with HPV infections of a specific type. For
instance, Koutsky et al. reported a 24 month risk of CIN-
2/3 following incident HPV-6 or -11 infection of
26%[13]. This compares to a figure of 1.9% observed over
the same time period in the present study, based on HPV
typing of lesion tissue specimens. Thus it is possible that
women with incident HPV-6 and -11 infections are clini-
cally at relatively high-risk for CIN-2/3 compared to other
women,[15] but that in the majority of cases, the lesions
are caused by other HPV types. In general, the exclusion of
disease testing positive for HPV types discordant from the
incident infection would be expected to yield lower esti-
mates of CIN risk following type-specific infection in the
present study, compared to previous analyses. Correlation
of HPV typing between infections and lesions can be par-
ticularly helpful for modeling studies evaluating HPV vac-
cines and tests[17,18], where risks associated with
individual HPV types or groups of types are typically of
interest.
The reporting of data for clinically detected CIN-1 as a dis-
tinct endpoint represents a second difference in analytic
method compared to most prior HPV natural history stud-
ies, which have focused upon CIN-2/3 development [13-
15]. Although CIN-2/3 represents a more proximate pre-
cursor to cervical cancer, CIN-1 is also often treated in
clinical practice in the US, 16and results in substantial
healthcare costs[6].
In the present study, the initial biopsy result showing evi-
dence of CIN was used for the purposes of denoting pro-
gression of infection to clinically detected CIN-1. These
women were not eligible to further contribute to the end-
points of CIN-2 or -3 should they have further progressed,
and some women with CIN-1 were subsequently treated,
thereby preventing progression. In most recent HPV natu-
ral history models[17,18], individual transition probabil-
ities have been utilized to model rapid progression from
HPV infection directly to CIN-2 or -3, more deliberate
progression of infection to CIN-1, and regression of HPV
infection. Additional health state transitions have been
used to model progression from CIN-1 to CIN-2, and
regression of CIN-1. Data in this study were analyzed in a
manner to inform each of the described transitions origi-
nating from HPV infection. Other studies describing pro-
gression and regression rates for CIN-1 have been
reviewed elsewhere [34-36].
Based on this perspective, risks of progression of incident
HPV infection to CIN-2/3 from the present analysis are
not directly comparable to those reported in prior natural
history studies where CIN-1 was not evaluated as a sepa-
rate endpoint [13-15]. All else equal, relatively lower risks
of progression to CIN-2/3 over time would be expected in
the present study, as cases of CIN-1 that otherwise may
have progressed to CIN-2/3, and been counted as CIN-2/
3 endpoints in prior analyses, were truncated at the point
of the initial CIN-1 diagnosis. Indeed, a study by Winer et
al. reported a 36 month risk of progression of HPV-16 and
-18 infections to CIN-2/3 (regardless of HPV type) of
27.2%, well above the 14.0% figure estimated in the
present analysis[14].
However, a common finding across studies has been the
relatively high risk of progression of HPV-16 and -18 to
cervical neoplasia compared to other HPV types [13-15],
with nearly one-third of women newly infected with these
types subsequently diagnosed with CIN in the present
study. Approximately 85% of HPV-6 and -11 infections
were observed to regress without resulting in a CIN diag-
nosis, however these HPV types cause 90–100% of condy-
loma acuminata, the classic form of genital warts[37,38].
This study adds HPV typing of 192 CIN-1 and 53 CIN-2/
3 lesion tissue specimens to previous US data for 190 CIN-
1 and 299 CIN-2/3 lesions respectively[30,31,39-43]. The
distribution of HPV types 6, 11, 16 and 18 in cervical
lesions was generally similar to that observed in aggregate
across prior studies. However, a small proportion of CIN-
2/3 lesions also tested positive for HPV-6 alone (5.7%) or
in combination with HPV-16 (1.9%). Since testing was
not conducted for types other than HPV 6, 11, 16 and 18
it is possible that other types were also present in combi-
nation with HPV-6. No CIN-2/3 lesions positive for HPV-
6 have been reported in prior US studies, however a large
US study of nearly 400 invasive cervical cancer tissue spec-
imens by Schwartz et al. revealed a prevalence of HPV-6
alone in 1.8% of cases, and HPV-6 in combination with
other types in 3.1% of cases[44]. The presence of HPV-6 in
CIN-2/3 lesions has not been examined in prior interna-
tional reviews and represents an area for further
research[45].
Limitations
A limitation of this study is that although liquid-based
cytology was conducted at 6 month intervals, with rigor-
ous follow-up of suspected abnormalities, and women
were referred for colposcopy at the conclusion of the
study, the detection of some CIN lesions may have been
missed or delayed. Thus, progression rates to CIN may be
conservative. A prior study of HPV natural history by
Winer et al. performed colposcopy at regularly scheduled
visits on all women and reported relatively higher risks ofInfectious Agents and Cancer 2007, 2:15 http://www.infectagentscancer.com/content/2/1/15
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progression to CIN-2/3[14]. However, as described previ-
ously, because HPV typing was not conducted for lesion
tissue specimens, and progression over time to CIN-1 was
not separately evaluated, all else equal, the risk of progres-
sion of specific HPV types to CIN-2/3 would be expected
to be somewhat liberal for disease modeling purposes. In
the absence of a single study overcoming the limitations
of both analyses, in our own HPV infection modeling
work[46], we have chosen to average estimates obtained
from the Winer and present study to account for the diver-
gent effects of these limitations.
Also, as previously noted, testing data were not available
in this study population for additional HPV types beyond
HPV 6, 11, 16 and 18. Thus, it was not possible to fully
characterize multi-type HPV infections in lesions where
present or explore the natural histories of other HPV
types.
Finally, women in the clinical trial were required to have
5 or fewer lifetime sexual partners at enrollment. In the
sub-sample of women examined in this analysis that
developed incident HPV 6, 11, 16 or 18 infections over
the course of follow-up, the median number of lifetime
sexual partners at the time of infection was five. There are
not published nationally representative US data on the
lifetime number of sexual partners among women devel-
oping incident HPV infections from which to make com-
parisons of external generalizability. However, in a further
investigation of this potential limitation, we found
through Cox regression analysis that the risk of develop-
ing CIN among women infected with HPV 6, 11, 16 or 18
did not vary by the lifetime number of sexual partners at
the time of infection (hazard ratio = 1.04; 95% CI 0.98–
1.11).
Conclusion
Over the past two decades there has been substantial
research demonstrating the causal link between HPV
infection and cervical neoplasia[47], and the relatively
high proportion of cervical cancers associated with certain
HPV types, particularly types 16 and 18[48]. With the
arrival of new technologies, such as HPV tests and vac-
cines targeting specific HPV types, there has also arisen a
need to accurately model the natural history of infection
for individual or groups of HPV types for policy evalua-
tions[9,10,17,18]. Epidemiologic studies to date have
generally not been specifically designed to evaluate HPV
infection or disease natural history in a manner ideal for
infectious disease modeling. This study has contributed
additional data for modeling outcomes of incident HPV 6,
11, 16 and 18 infections. However, further studies with
rigorous disease ascertainment would be helpful, particu-
larly for incident infections caused by other HPV types,
Sample selection criteria for analyses of incident HPV 6, 11,  16 and 18 infections Figure 1
Sample selection criteria for analyses of incident 
HPV 6, 11, 16 and 18 infections. The final samples of 
women with incident HPV infections eligible for each type-
specific analysis are represented within the bottom box, 
labeled by HPV type. These were comprised of placebo arm 
women with incident type-specific infections who were nega-
tive on PCR testing for the relevant HPV type on the first 
two trial endo/ecto-cervical swabs and any intervening cervi-
cal biopsies.
Full trial population  
(vaccine and placebo arms) 
(n = 2,391) 
Placebo arm enrollees with baseline 
HPV testing 
(n = 1,203) 
With ≥ 3 visits with satisfactory 
endo/ecto-cervical swab PCR results 
for the respective HPV type 
HPV 6    (n = 1,003) 
HPV 11  (n = 1,003) 
HPV 16  (n = 1,002) 
HPV 18  (n = 1,002) 
PCR negative for the respective HPV 
type on the first two trial swabs and 
any intervening biopsies   
HPV 6    (n = 953) 
HPV 11  (n = 995) 
HPV 16  (n = 895) 
HPV 18  (n = 963) 
Incident infections - PCR positive for 
the respective HPV type on a cervical 
swab or biopsy specimen following 
the date of the second trial swab 
HPV 6    (n = 103) 
                HPV 11  (n = 13) 
                HPV 16  (n = 142) 
                HPV 18  (n = 62) Infectious Agents and Cancer 2007, 2:15 http://www.infectagentscancer.com/content/2/1/15
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and the progression and regression of incident cervical
neoplasia caused by specific HPV types.
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